Eledon Pharmaceuticals, Inc.
ELDN Nasdaq
SEC CIK 1404281
Follow Eledon Pharmaceuticals
Weekly email: filings, results
Net income
−$3.9M
+77.5% vs same quarter last year
EPS, diluted
−$0.03
+85.7% vs same quarter last year
Operating cash flow
−$19M
−31.1% vs same quarter last year
Operating income
−$21.7M
−13.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | - | −$45.6M |
| FY24 | - | −$36.2M |
| FY23 | - | −$116.5M |
| FY22 | - | −$88M |
| FY21 | - | −$34.5M |
| FY20 | - | −$22.8M |
| FY19 | - | −$16M |
| FY18 | - | −$14.1M |
| FY17 | - | −$13.1M |
| FY16 | $0 | −$5.7M |
| FY15 | $0 | −$45.1M |
| FY14 | $0 | −$23.3M |
| FY13 | $0 | −$15.7M |
| FY12 | $0 | −$9.6M |
| FY11 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | - |
| FY23 | - |
| FY22 | - |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | −$4.9M |
| FY15 | −$41.8M |
| FY14 | −$21.1M |
| FY13 | −$15.5M |
| FY12 | −$9.3M |
| FY11 | - |